Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + paclitaxel + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three agents: - **Carboplatin** (a platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis in rapidly dividing cells) - **Paclitaxel** (a taxane-class chemotherapeutic that stabilizes microtubules, inhibiting cell division) - **Toripalimab** (a monoclonal antibody immune checkpoint inhibitor targeting PD-1, enhancing T-cell mediated anti-tumor immunity). The combination is being investigated primarily as a neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma (ESCC). Clinical studies have shown this regimen to be safe, feasible, and effective in this setting, with notable rates of major pathological response and complete response. Toripalimab augments the anti-tumor effect of chemotherapy by blocking PD-1-mediated immunosuppression within the tumor microenvironment[1][2][4].
- Brand names
- TuoyiLoqtorziParaplatinTaxol
- Other names
- Toripalimab + carboplatin + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + paclitaxel + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + paclitaxel + toripalimab.